Last reviewed 2026-05-26 · How we verify

rAdp53 plus cisplatin

Shenzhen SiBiono GeneTech Co.,Ltd · Phase 2 active Small molecule ✓ Verified May 2026

rAdp53 plus cisplatin is a Small molecule drug developed by Shenzhen SiBiono GeneTech Co.,Ltd. It is currently in Phase 2 development.

Researchers studied the combination of rAdp53 and cisplatin in a phase 2 clinical trial for the treatment of malignant pleural effusion. Cisplatin is a small molecule, classified as a chemotherapeutic agent, used in combination with rAdp53 in this study.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	rAdp53 plus cisplatin
Sponsor	Shenzhen SiBiono GeneTech Co.,Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

rAdp53 plus cisplatin CI brief — competitive landscape report
rAdp53 plus cisplatin updates RSS · CI watch RSS
Shenzhen SiBiono GeneTech Co.,Ltd portfolio CI

Frequently asked questions about rAdp53 plus cisplatin

What is rAdp53 plus cisplatin?

rAdp53 plus cisplatin is a Small molecule drug developed by Shenzhen SiBiono GeneTech Co.,Ltd.

Who makes rAdp53 plus cisplatin?

rAdp53 plus cisplatin is developed by Shenzhen SiBiono GeneTech Co.,Ltd (see full Shenzhen SiBiono GeneTech Co.,Ltd pipeline at /company/shenzhen-sibiono-genetech-co-ltd).

What development phase is rAdp53 plus cisplatin in?

rAdp53 plus cisplatin is in Phase 2.

Manufacturer: Shenzhen SiBiono GeneTech Co.,Ltd — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing